Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

NCT04419467 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT04419467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04419467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
Lead sponsor
CSL Behring
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2020
Completion date
October 24, 2022
Enrollment
114 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease (dkd)